相关临床试验
1253
231 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1810
终止
26
2.1%
招募中
225
18.0%
暂停
3
0.2%
撤回
20
1.6%
进行中（未招募）
149
11.9%
Unknown
61
4.9%
已完成
687
54.8%
Enrolling By Invitation
19
1.5%
尚未招募
63
5.0%
暂无批准数据
- A new Landmark Perspective in Science marks the 50th anniversary of Robert C. Gallo's 1976 discovery of a human T-cell growth factor later named interleukin-2 (IL-2). - The discovery enabled long-term culture of human T cells, leading to identification of the first human retroviruses HTLV-1 and HTLV-2 and establishing human retrovirology. - The same capability proved critical to characterizing HIV as the cause of AIDS and to developing the HIV blood test, improving global blood supply safety. - IL-2 also underpinned cellular immunotherapy advances including tumor-infiltrating lymphocyte therapy and CAR-T cell therapy, with scientific exchange continuing in Venice in 2027.
- A Swedish national registry study of more than 6.3 million individuals found that 11.2% had at least one autoimmune disease, with 1.3% carrying more than one such diagnosis. - Researchers found no evidence of a single common genetic basis across all 22 autoimmune diseases studied, instead identifying distinct genetic clusters tied to affected tissues. - Connective tissue, endocrine, and gastrointestinal autoimmune diseases each formed separate genetic clusters, while nervous system diseases showed weaker genetic links. - The findings, published in The Journal of Clinical Investigation, provide a broader picture of how different autoimmune diseases share genetic risk.
- The Center for Heart Failure and Arrhythmia, led by Gianluigi Savarese at Karolinska Institutet, published an extensive body of 2026 research across leading cardiovascular journals. - New studies address heart failure epidemiology, guideline-directed pharmacotherapy, and outcomes in journals including the European Journal of Heart Failure and Journal of Cardiac Failure. - Collaborative work with international investigators such as Javed Butler, Marco Metra, and Stefan Anker highlights multinational analyses of heart failure treatment and prognosis. - The portfolio underscores the center's role in advancing evidence on heart failure management, arrhythmia, and cardio-oncology through registry-based and clinical research.
- Karolinska Institutet's website, ki.se, is temporarily closed due to technical maintenance, with the institution working to restore service as soon as possible. - Visitors are directed to contact the university through alternative channels, including phone, email, and the press office, during the outage. - The notice provides contact details for students, staff, and the public, including the switchboard, registry office, and university library.
- A new four-part webinar series from Bioculture Group, EARA, and Xtalks will examine the science, regulation, and responsibility behind non-human primate (NHP) use in biomedical research. - The opening session, scheduled for September 25, 2026, will compare NHP models with emerging new approach methodologies (NAMs) such as organ-on-chip and AI-driven models. - Panelists will present a real-world preclinical case study illustrating how NHP-derived data informed downstream clinical decision-making and shaped a therapeutic program. - The series supports the 3Rs principles (Replacement, Reduction, Refinement) and addresses scientific, ethical, and regulatory factors guiding model selection.
- A nationwide Swedish study of over 7,300 patients found that NOACs slowed cognitive decline by slightly more than 0.2 MMSE points per year compared with warfarin or no anticoagulant. - NOAC users also had lower risks of death, stroke, blood clots, and fractures, without increasing major bleeding risk, unlike warfarin. - The observational study, published in the European Heart Journal, suggests NOACs may offer neuroprotective benefits beyond stroke prevention but requires randomized trials to confirm. - Researchers from Karolinska Institutet note that NOACs are easier to use and safer than warfarin, which may partly explain better outcomes in patients with cognitive impairment.
- Two Karolinska Institutet professors receive Proof-of-Concept grants from the Knut and Alice Wallenberg Foundation and SciLifeLab in the 2026 call for proposals. - Gonçalo Castelo-Branco's project focuses on Transposome-based Ligase (TbL) technology for advancing clinical epigenomics applications. - Janne Lehtiö's NEO-SCOPE project aims to enable neoantigen discovery at full genomic scale for precision immunotherapy development. - The program has funded 158 projects since 2017, providing SEK 1–4 million each with support from the Wallenberg Launch Pad team.
- Researchers in Bordeaux have identified TRIM47, a protective protein that helps maintain vascular integrity in the brain by activating the NRF2 antioxidant pathway, opening new therapeutic avenues for CSVD. - Two strategies are being explored: antisense oligonucleotides targeting KEAP1 to boost the TRIM47/NRF2 pathway, and repurposing existing drugs like multiple sclerosis therapies that activate NRF2. - Helena Karlström's group at Karolinska Institutet received a Novo Nordisk Pioneer Innovator Grant to develop monoclonal antibodies that clear harmful NOTCH3 protein aggregates in CADASIL, a rare genetic form of CSVD. - CSVD affects over 5 million people in France alone and is the second most common cause of dementia after Alzheimer's disease, yet no curative treatment currently exists.
- Nature Medicine published an article describing the Nordic AI-Health Initiative, a proposed platform built on large-scale longitudinal and multimodal health datasets from across the Nordic region. - Karolinska Institutet's Centre for AI Innovation (CAII) is highlighted as a key asset, providing the computational, technical, and collaborative environment for advanced health AI development. - The Swedish TEF-Health node supports testing, validation, benchmarking, and regulatory readiness of AI solutions in real healthcare settings, serving as a deployment and validation layer. - Together, CAII and TEF-Health provide complementary capabilities to transform Nordic health data assets into validated, deployable AI solutions with clinical and societal impact.
- In a study of over 12,000 men, the Stockholm3 blood test identified 90% of aggressive prostate cancer cases compared to 74% for the standard PSA test. - Stockholm3 missed significantly fewer aggressive cancers than PSA without increasing the number of unnecessary follow-ups or false positives. - Early detection is critical as the five-year survival rate for prostate cancer confined to the prostate is nearly 100%. - A3P Biomedical plans to pursue FDA approval for Stockholm3 and will generate U.S. data to support routine screening use.
